drugset

drugset / Trial / NCT02425579

Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

NCT02425579 ↗

Phase 1 Completed 12 enrolled Brigham and Women's Hospital Duke University · collab Massachusetts General Hospital · collab Weill Medical College of Cornell University · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety of inhaled carbon monoxide (iCO) in intubated patients with sepsis-induced ARDS.

Timeline

Start: 2015-04
Primary completion: 2019-08
Completion: 2019-08

Publications

Fredenburgh LE, Perrella MA, Barragan-Bradford D, Hess DR, Peters E, Welty-Wolf KE, Kraft BD, Harris RS, Maurer R, Nakahira K, Oromendia C, Davies JD, Higuera A, Schiffer KT, Englert JA, Dieffenbach PB, Berlin DA, Lagambina S, Bouthot M, Sullivan AI, Nuccio PF, Kone MT, Malik MJ, Porras MAP, Finkelsztein E, Winkler T, Hurwitz S, Serhan CN, Piantadosi CA, Baron RM, Thompson BT, Choi AM. A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. JCI Insight. 2018 Dec 6;3(23):e124039. doi: 10.1172/jci.insight.124039.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Inhaled Carbon Monoxide	Unknown	100 ppm	Inhaled
Subject	Inhaled Carbon Monoxide	Unknown	200 ppm	Inhaled

Indications